Publication | Closed Access

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

ThrombosisMetabolic SyndromeMixed Lipid DisordersHmg-coa Reductase InhibitorsLipid DisorderCardiovascular DiseaseMedicineLipid DisordersHyperlipidemiaPharmacotherapyCombination GemfibrozilLipoprotein MetabolismPharmacologyAtherosclerosisDyslipidemiaHealth Sciences